An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. - sprookjes - yvandenbroek - TriplyDB

An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.

An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.

http://www.wikidata.org/entity/Q36610246

about

An integrative proteomics and interaction network-based classifier for prostate cancer diagnosis Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer Molecular pathways and targets in prostate cancer PTEN and Ki67 expression is associated with clinicopathologic features of non-small cell lung cancer.ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer Expression of ERG protein in prostate cancer: variability and biological correlates.Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.Prostate cancer: the need for biomarkers and new therapeutic targets.Therapeutic Approaches Targeting MYC-Driven Prostate Cancer Maintaining and reprogramming genomic androgen receptor activity in prostate cancer.Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Exploring the molecular targets of dietary flavonoid fisetin in cancer.Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer-a targeted molecular approach Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients.A five-variable signature predicts radioresistance and prognosis in nasopharyngeal carcinoma patients receiving radical radiotherapy.PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort.Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'?PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy.MYC overexpression at the protein and mRNA level and cancer outcomes among men treated with radical prostatectomy for prostate cancer.Epigenetic alterations in TRAMP mice: epigenome DNA methylation profiling using MeDIP-seq.Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy.

P2860

Q28533442-D55CD534-D7D4-4945-B4AB-C6CA0B0C4548 Q28546607-5EDCA6A4-3BCC-4366-8A45-485CEAA65A86 Q34365632-65DD8C53-2585-43E1-8E10-E1BFCDB5C703 Q34606601-6FE35D3A-A4CC-4A56-8C63-421BFEE19280 Q35091321-E545604A-7DC9-4A2E-9AB3-99D8B9B3567D Q35406347-8A3D7722-A7FA-4F75-AD79-E5328518CBEB Q35608000-7F41E0EA-EC82-4B69-8912-8F63D2F0C7BB Q35619493-EF11B8E2-6A50-4C49-BE32-3C86AB6C289C Q36199762-B421150A-919E-4D7E-84A2-EAD10ECBE30E Q36269232-8460B2C1-0859-444F-86E6-394AFD44A15A Q36469889-3A71E66B-E342-4F11-953C-24D2C3E7E90D Q36887707-CE2936B6-06DD-47E1-9ABC-DADCFA944791 Q36959119-E4B17AA1-A8E8-4BB4-855C-50699424F87C Q37156611-EF3607E7-84EC-4E76-B4DC-7DA76AFB0F94 Q37476043-D7EB85BD-C0E0-4127-8B3E-2176E010502B Q37676253-60FDA596-2E8A-41B2-89D6-CA389DF3871B Q38190362-72C12F03-F131-4D66-A1D3-8733B2B48F5E Q38540198-D8FD05C6-E07B-4938-A61B-411E7B173282 Q38774228-F110E11D-4582-4A5D-9E69-DE1ED35D09BF Q38830924-0F459FDE-926B-4726-9831-C384344D9271 Q38833458-95D03DF9-8D18-4ED7-A44E-15856E49AD90 Q38849399-8465B6A4-5CD1-4818-AD85-24B09F4696FC Q39044979-FBB5EC5D-412E-4F82-B5F3-D452DA28D38B Q39401816-7101EC27-75A4-4E84-BB9A-AB93D3F3F9BC Q40656134-288E36AA-38DC-4E7E-9838-8F04074394CF Q41140848-6EBB16F5-DC28-49EE-AA2C-E0F426C5AC8F Q41308391-73DDAF04-6208-4CD9-95F0-D10508A4EA02 Q41907553-60BF4E32-4D6D-49AB-A9DF-689755C170CD Q42184292-4286CB26-D0C5-410A-B2CA-E18F2BAD21C1 Q42250126-A366C1CB-B9A5-4E99-B0A4-B670E0A37337 Q42371556-75114815-78EE-41FC-B155-0351842CAEBE Q42756677-D8416FE0-A5FE-4DC5-9634-782CD6110D64 Q43089446-BC0AC670-F004-446C-886F-AB012614E52B Q43104641-E5F567E8-316D-453F-928B-4D5C9945325C Q47399099-653E9752-EB7B-42EE-A102-49EB035C1A49 Q49985254-35708570-CD6B-42CD-BD18-BE5706E42810 Q53025231-80FFBDAB-E749-48BF-BF6B-9A0B1B8AE9DD Q53082540-E21684B1-6C8E-4922-8E9A-1BC0EE47ECBF

P2860

An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.

http://www.wikidata.org/entity/Q36610246

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

An immunohistochemical signatu ...... docetaxel after prostatectomy.

@ast

An immunohistochemical signatu ...... docetaxel after prostatectomy.

@en

type

label

An immunohistochemical signatu ...... docetaxel after prostatectomy.

@ast

An immunohistochemical signatu ...... docetaxel after prostatectomy.

@en

prefLabel

An immunohistochemical signatu ...... docetaxel after prostatectomy.

@ast

An immunohistochemical signatu ...... docetaxel after prostatectomy.

@en

P1433

Q36610246-4101BE84-3E60-490D-8577-2D817AA7127D

P1476

Q36610246-0C75A1CF-C39E-4FBF-AEC0-461533B76530

P2093

Q36610246-076ED930-369D-46E9-A7F9-578E8C2DEC74

Q36610246-0EABFAAB-A48F-4F87-8060-C91A0B8CA392

Q36610246-131928CF-330B-4727-828C-0C4045C80515

Q36610246-187393BF-3654-49EF-8A12-0D26FAB2D884

Q36610246-3343A6E5-F801-42CB-A1EC-0F69E6AD0999

Q36610246-A3E8A6C3-8457-43AD-8FEE-7326259D8AFB

Q36610246-BF4194B3-025B-4803-B1AC-88FEC220176C

Q36610246-BFE7B0AF-F50F-49DB-B024-693B8AF21979

Q36610246-D0E2ACD0-14BF-44FE-8305-3DCA05509B93

P2860

Q36610246-0974191B-845B-43C0-999C-BB147C35B180

Q36610246-0D466BCA-0A44-4356-B1A8-4B922F29BEF0

Q36610246-0D6BC32D-9843-4F7E-90F5-56E2F4BCA7F2

Q36610246-0E2AC033-4F69-495E-8DD9-9658EC356B7D

Q36610246-180452E8-6A90-4150-A9D1-356A48F9BA60

Q36610246-291457F2-3D07-46D7-B35C-036042998811

Q36610246-32B8AAF9-07FF-4D5D-8F38-8E71FB2DE412

Q36610246-38740E83-C41F-4714-8468-00544B9A7ECA

Q36610246-39069AEA-5942-4AEC-8C59-5F4E4CF48FC5

Q36610246-3A2E76DF-036B-4BFE-9840-495E33206FDD

P304

Q36610246-BD718F2A-0502-4B7C-AA8B-D7D65350AD39

P31

Q36610246-CFDFA761-DD8B-4C1F-B596-6ACA8A3140F4

P356

Q36610246-012DD5EE-0049-4002-B8E8-6551686F0009

P407

Q36610246-C13ED7C1-02D6-4DA3-87C3-19D5BCDDFF30

P433

Q36610246-513DF5F2-FA13-4304-9A7B-060A37864DE9

P478

Q36610246-5246D736-4399-481D-B1AA-79E7A2080DE8

P50

Q36610246-E4FA4013-F9D1-42F8-8EC2-7AF78F0BEFF5

P577

Q36610246-88D2BB1F-88C1-4FEF-B913-2D818C54FAC5

P5875

Q36610246-FA0E99DA-CAB6-4ACE-B28E-18F09A9251CB

P698

Q36610246-42396F3F-F1C2-4A26-9130-210AE11A644C

P932

Q36610246-7B31C46E-C9EC-47D1-9915-521A8D517711

P356

P1433

P1476

An immunohistochemical signatu ...... docetaxel after prostatectomy.

@en

P2093

Angelo M De Marzo

http://www.w3.org/2001/XMLSchema#string

Bora Gurel

http://www.w3.org/2001/XMLSchema#string

Daniel Keizman

http://www.w3.org/2001/XMLSchema#string

Emmanuel S Antonarakis

http://www.w3.org/2001/XMLSchema#string

Helen L Fedor

http://www.w3.org/2001/XMLSchema#string

Jessica L Hicks

http://www.w3.org/2001/XMLSchema#string

Mario A Eisenberger

http://www.w3.org/2001/XMLSchema#string

Michael A Carducci

http://www.w3.org/2001/XMLSchema#string

Zhe Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Defining the role of mTOR in cancer

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

Practical methods for tissue microarray construction.

Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene.

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.

P304

6063-6071

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.27689

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225275696

http://www.w3.org/2001/XMLSchema#string

P698

22674438

http://www.w3.org/2001/XMLSchema#string

P932

3572534

http://www.w3.org/2001/XMLSchema#string